'New Era' in the Treatment of Rare Lymphoma'New Era' in the Treatment of Rare Lymphoma

Ibrutinib is the first drug approved for the treatment of Waldenström's macroglobulinemia, and new data strengthen its profile. Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news